# Collegium (COLL) — News

COLL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/coll/news

## Recent headlines

- [Collegium Pharmaceutical, Inc.: Truist Securities cuts target price to $49 from $58](https://www.ainvest.com/news/collegium-pharmaceutical-truist-securities-cuts-target-price-49-58-2609) — AInvest Wire, Sep 9, 2026
- [Collegium Pharmaceutical, Inc.: Leerink partners initiates coverage with outperform rating; price target $45](https://www.ainvest.com/news/collegium-pharmaceutical-leerink-partners-initiates-coverage-outperform-rating-price-target-45-2609) — AInvest Wire, Sep 9, 2026
- [Collegium Pharmaceutical Q2 adjusted EPS USD 1.92 vs. IBES estimate USD 1.72](https://www.ainvest.com/news/collegium-pharmaceutical-q2-adjusted-eps-usd-1-92-ibes-estimate-usd-1-72-2608) — AInvest Wire, Aug 6, 2026
  Collegium Pharmaceutical (COLL) reported second-quarter adjusted earnings per share (EPS) of USD 1.92, exceeding the IBES estimate of USD 1.72, according to recent financial results. The company also posted Q2 revenue of USD 188 million, surpassing the IBES revenue forecast of USD 180.9 million.…
- [Collegium Pharmaceutical outlook FY revenue USD 825-855 million](https://www.ainvest.com/news/collegium-pharmaceutical-outlook-fy-revenue-usd-825-855-million-2608) — AInvest Wire, Aug 6, 2026
- [Coll sees FY adj. EBITDA $445M to $470M, saw $475M to $500M](https://www.ainvest.com/news/coll-sees-fy-ebitda-445m-470m-475m-500m-2608) — AInvest Wire, Aug 6, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).